FY2026 · period end Mar '26 · from the 10-K filed Jun 2, 2026
| Metric | FY26Mar '26 | FY25Mar '25 | FY24Mar '24 | FY23Mar '23 | FY22Mar '22 |
|---|---|---|---|---|---|
| Revenue | $0.18B | $0.23B | $0.27B | $0.25B | $0.27B |
| Gross Profit | $0.05B | $0.07B | $0.08B | $0.08B | $0.08B |
| Operating Income | negative: -$0.06B | negative: -$0.00B | negative: -$0.01B | $0.01B | $0.02B |
| Net Income | negative: -$0.06B | negative: -$0.01B | negative: -$0.01B | $0.01B | $0.02B |
| EPS (Diluted) | negative: -$2.74 | negative: -$0.30 | negative: -$0.37 | $0.25 | $0.92 |
| Metric | FY26Mar '26 | FY25Mar '25 | FY24Mar '24 | FY23Mar '23 | FY22Mar '22 |
|---|---|---|---|---|---|
| Total Assets | $0.08B | $0.15B | $0.17B | $0.17B | $0.18B |
| Total Liabilities | $0.05B | $0.06B | $0.07B | $0.06B | $0.06B |
| Stockholders' Equity | $0.03B | $0.09B | $0.10B | $0.11B | $0.12B |
| Cash & Equivalents | $0.02B | $0.05B | $0.06B | $0.10B | $0.11B |
| Total Debt | — | — | — | — | — |
| Metric | FY26Mar '26 | FY25Mar '25 | FY24Mar '24 | FY23Mar '23 | FY22Mar '22 |
|---|---|---|---|---|---|
| Operating Cash Flow | negative: -$0.03B | $0.00B | $0.00B | $0.03B | $0.02B |
| Capital Expenditures | $0.00B | $0.01B | $0.00B | $0.01B | $0.00B |
| Free Cash Flow | negative: -$0.03B | negative: -$0.00B | negative: -$0.00B | $0.02B | $0.02B |
| Metric | FY26Mar '26 | FY25Mar '25 | FY24Mar '24 | FY23Mar '23 | FY22Mar '22 |
|---|---|---|---|---|---|
| Gross Margin | 28.1% | 30.5% | 30.9% | 30.9% | 28.3% |
| Operating Margin | negative: -0.3% | negative: -0.0% | negative: -0.0% | 0.0% | 0.1% |
| Net Margin | negative: -0.3% | negative: -0.0% | negative: -0.0% | 0.0% | 0.1% |
| Return on Equity | negative: -100.4% | negative: -6.9% | negative: -7.2% | 4.4% | 15.1% |
| Return on Assets | negative: -49.8% | negative: -3.9% | negative: -4.4% | 3.0% | 10.2% |
| Debt / Equity | — | — | — | — | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001040130-26-000041 | Jun 30, 2026 | Aug 13, 2026 | Aug 13, 2026 20:58 UTC | EDGAR |
| 8-K | 0001040130-26-000040 | Aug 13, 2026 | Aug 13, 2026 | Aug 13, 2026 20:17 UTC | EDGAR |
| 8-K | 0001040130-26-000036 | Aug 11, 2026 | Aug 12, 2026 | Aug 12, 2026 20:30 UTC | EDGAR |
| 8-K | 0001040130-26-000029 | Jul 23, 2026 | Jul 23, 2026 | Jul 23, 2026 13:26 UTC | EDGAR |
| 8-K | 0001040130-26-000027 | Jun 23, 2026 | Jun 26, 2026 | Jun 26, 2026 20:10 UTC | EDGAR |
| 10-K | 0001040130-26-000019 | Mar 31, 2026 | Jun 2, 2026 | Jun 2, 2026 20:55 UTC | EDGAR |
| 8-K | 0001040130-26-000016 | Jun 2, 2026 | Jun 2, 2026 | Jun 2, 2026 20:15 UTC | EDGAR |
| 8-K | 0001040130-26-000010 | May 15, 2026 | May 21, 2026 | May 21, 2026 20:40 UTC | EDGAR |
Direct links to SEC EDGAR. PETS has additional filings available on the SEC site.
6 numbers PETMED EXPRESS INC later changed — same XBRL tag, both filings linked.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2023
Major restatementwas$1.6M
Revised up in a 10-K.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q2 2023
Major restatementwas$383K
Revised up in a 10-Q.
Liabilities·As of Dec 31, 2022
Major restatementwas$31.5M
Revised up in a 10-Q.
Liabilities·As of Mar 31, 2022
Major restatementwas$34.1M
Revised up in a 10-K/A.
Liabilities·As of Mar 31, 2023
Major restatementwas$40.3M
Revised up in a 10-K.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q1 2023
Major restatementwas-$1M
Revised down in a 10-Q.
PETS is not the only one.
See every restatement we've found across the market — or get an alert the next time PETS revises a number.
Restatements are detected by comparing every vintage of a fact across all of PETMED EXPRESS INC's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows PETS's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling PETMED EXPRESS INC — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on PETS yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on PETS and publish the result to your public profile.
Ask about PETMED EXPRESS INC
Continue in Workspace — cited answers on PETS, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs